India, March 19 -- Roivant Sciences Ltd. (ROIV), a biopharmaceutical company, announced Wednesday that its clinical-stage immunology unit Immunovant Inc.(IMVT) reported positive topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
In pre-market activity on the Nasdaq, Immunovant shares were losing around 11.1 percent to trade at $16.70, and Roivant Sciences shares were down 3% at $10.39.
Immunovant plans to initiate potentially registrational studies in both MG and CIDP with lead asset IMVT-1402 and has received clearance for its Investigational New Drug or IND applications for both indications, as announced earlier.
Roivant added that Immunovant at present does not i...